RxDoctor Payments Data

Jimena Blandon, MD

Internal Medicine · Miami, FLNPI 1922319003

Payments from drug & device makers

$244,265in general payments, 2019–2025

Across 14 payments — averaging $17,447 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$166K
  • Vertex$76K
  • Melinta Therapeutics, LLC$473
  • Urovant Sciences Inc$390
  • Vifor Pharma, Inc.$325
  • GSK$126
  • plus $75 from 3 others
$645in research payments, 2019–2025

Across 1 payment — averaging $644.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$645

What the payments were for

  • Consulting fees$95369%
  • Speaking & faculty fees$20014%
  • Food & beverage$23617%

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$244,265 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$36,702
Medicare patients
95
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$7,075
Diclofenac Sodium18$410
Bumetanide11$265
CefuroximeCefuroxime Axetil14$261
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav30$204
Methylprednisolone26$168
Dicyclomine Hcl17$152
Famotidine28$132
Azithromycin15$129
Pantoprazole Sodium21$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$7,07512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →